Anti-CD137 antigen-binding molecule and utilization thereof

PH12021500011B1Active Publication Date: 2026-08-28CHUGAI PHARMA CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
PH12021500011
Authority / Receiving Office
PH · PH
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-02-09
Publication Date
2026-08-28
Estimated Expiration
2041-02-09
Patent Text Reader

Abstract

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same. Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on nontumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided. The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.
Need to check novelty before this filing date? Find Prior Art